Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18344405 | Azetidinyl Pyrimidines and Uses Thereof | Non-Final OA | Alcon Inc. |
| 18564384 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | Non-Final OA | Aurigene Oncology Limited |
| 18043389 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18275692 | SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18270613 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | Non-Final OA | Duke University |
| 18258989 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 17909941 | CERAMIDE GROWTH PROMOTING AGENT | Final Rejection | TAKASAGO INTERNATIONAL CORPORATION |
| 18033055 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Non-Final OA | Azura Ophthalmics Ltd. |
| 18572867 | EGFR INHIBITORS | Non-Final OA | Blueprint Medicines Corporation |
| 18568840 | Heteroaryl compounds as inhibitors of TYK2, composition and application thereof | Non-Final OA | Accro Bioscience (HK) Limited |
| 18367631 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | Non-Final OA | Opus Genetics, Inc. |
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Non-Final OA | Maze Therapeutics, Inc. |
| 18285807 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Non-Final OA | HemoShear Therapeutics, Inc. |
| 18549968 | TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA | Non-Final OA | Shenzhen Evergreen Therapeutics Co., Ltd |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | Non-Final OA | Idorsia Pharmaceuticals Ltd |
| 17909162 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | Non-Final OA | CENTESSA PHARMACEUTICALS (UK) LIMITED |
| 18035770 | Heterocyclic Compound and Preparation Method and Use Thereof | Non-Final OA | SYNTRON (JIANGSU) PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 17794757 | Cellular Uptake | Non-Final OA | Axcess (UK) Ltd |
| 17631596 | JAK KINASE INHIBITOR AND USE THEREOF | Final Rejection | JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. |
| 17598695 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITYIN THE CITY OF NEW YORK |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy